DOW JONES NEWSWIRES
Gilead Sciences Inc. (GILD) on Friday disclosed it received a
subpoena from the Department of Justice requesting documents
related to the manufacturing and distribution practices of several
of the biopharmaceutical company's treatments.
Shares of Gilead slid 3.1% to $39 in after-hours trading.
The company said the subpoena was from the U.S. Attorney's
Office for the Northern District of California and focused on
treatments including Atripla, Hepsera, Letairis and Truvada.
Gilead also said it was cooperating with the civil and criminal
investigation.
The company has dominated the market for HIV treatment and
receives royalties from Roche Holdings AG (RHHBY, ROG.VX) for
Tamiflu, which Gilead discovered. In April, Gilead reported its
first-quarter profit slid 24% as income from royalties declined
sharply and operating margin narrowed.
-By John Kell, Dow Jones Newswires; 212-416-2480;
john.kell@dowjones.com